Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Predicting Durable Anti-tumor Immune Responses after Cancer Vaccines.
Journal: Journal of cancer immunology
Published: June 11, 2026
Safety and immunogenicity of a tri-antigen vaccine targeting IGFBP-2, HER2, and IGF-IR in participants with non-metastatic breast cancer.
Journal: Journal for immunotherapy of cancer
Published: April 07, 2026
Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses.
Journal: Journal of gynecologic oncology
Published: January 19, 2026
An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044).
Journal: Gynecologic oncology
Published: December 16, 2024
Magnitude of antigen-specific T-cell immunity the month after completing vaccination series predicts the development of long-term persistence of antitumor immune response.
Journal: Journal for immunotherapy of cancer
Published: October 11, 2024
Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer.
Journal: Gynecologic oncology
Published: August 09, 2024
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer.
Journal: Journal for immunotherapy of cancer
Published: April 28, 2023
Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study.
Journal: European journal of gynaecological oncology
Published: March 06, 2023
Uterine lavage identifies cancer mutations and increased TP53 somatic mutation burden in individuals with ovarian cancer.
Journal: Cancer research communications
Published: October 31, 2022
Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates.
Journal: Journal for immunotherapy of cancer
Published: August 11, 2021
Immunization with a Plasmid DNA Vaccine Encoding the N-Terminus of Insulin-like Growth Factor Binding Protein-2 in Advanced Ovarian Cancer Leads to High-level Type I Immune Responses.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 29, 2021
Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma.
Journal: Gynecologic oncology
Published: January 27, 2019
Last Updated: 09/26/2026